Preferential HLA-B27 allorecognition displayed by multiple cross-reactive antiviral CD8+ T cell receptors by Rowntree, Louise C. et al.
ORIGINAL RESEARCH
published: 19 February 2020
doi: 10.3389/fimmu.2020.00248
Frontiers in Immunology | www.frontiersin.org 1 February 2020 | Volume 11 | Article 248
Edited by:
Babita Agrawal,
University of Alberta, Canada
Reviewed by:
Markus Cornberg,
Hannover Medical School, Germany
Sarah Rowland-Jones,
University of Oxford, United Kingdom
*Correspondence:
Nicole A. Mifsud
nicole.mifsud@monash.edu
Specialty section:
This article was submitted to
Viral Immunology,
a section of the journal
Frontiers in Immunology
Received: 23 October 2019
Accepted: 30 January 2020
Published: 19 February 2020
Citation:
Rowntree LC, van den Heuvel H,
Sun J, D’Orsogna LJ, Nguyen THO,
Claas FHJ, Rossjohn J,
Kotsimbos TC, Purcell AW and
Mifsud NA (2020) Preferential
HLA-B27 Allorecognition Displayed by
Multiple Cross-Reactive Antiviral
CD8+ T Cell Receptors.
Front. Immunol. 11:248.
doi: 10.3389/fimmu.2020.00248
Preferential HLA-B27 Allorecognition
Displayed by Multiple Cross-Reactive
Antiviral CD8+ T Cell Receptors
Louise C. Rowntree 1,2,3, Heleen van den Heuvel 3,4, Jessica Sun 3, Lloyd J. D’Orsogna 5,6,
Thi H. O. Nguyen 7, Frans H. J. Claas 4, Jamie Rossjohn 3,8,9, Tom C. Kotsimbos 1,2,
Anthony W. Purcell 3 and Nicole A. Mifsud 1,2,3*
1 Respiratory Medicine Laboratory, Department of Medicine, Central Clinical School, Monash University, Melbourne, VIC,
Australia, 2Department of Allergy, Immunology, and Respiratory Medicine, The Alfred Hospital, Melbourne, VIC, Australia,
3 Infection and Immunity Program, Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute,
Monash University, Clayton, VIC, Australia, 4Department of Immunohaematology and Blood Transfusion, Leiden University
Medical Center, Leiden, Netherlands, 5Department of Clinical Immunology and Pathwest, Fiona Stanley Hospital, Perth, WA,
Australia, 6 School of Medicine, University of Western Australia, Perth, WA, Australia, 7Department of Microbiology and
Immunology, Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Parkville, VIC, Australia,
8 Australian Research Council Centre of Excellence for Advanced Molecular Imaging, Monash University, Clayton, VIC,
Australia, 9 Institute of Infection and Immunity, Cardiff University School of Medicine, Heath Park, Cardiff, United Kingdom
T cells provide essential immunosurveillance to combat and eliminate infection from
pathogens, yet these cells can also induce unwanted immune responses via T
cell receptor (TCR) cross-reactivity, also known as heterologous immunity. Indeed,
pathogen-induced TCR cross-reactivity has shown to be a common, robust, and
functionally potent mechanism that can trigger a spectrum of human immunopathologies
associated with either transplant rejection, drug allergy, and autoimmunity. Here, we
report that several virus-specific CD8+ T cells directed against peptides derived from
chronic viruses (EBV, CMV, and HIV-1) presented by high frequency HLA-A and -B
allomorphs differentially cross-react toward HLA-B27 allotypes in a highly focused and
hierarchical manner. Given the commonality of cross-reactive T cells and their potential
contribution to adverse outcomes in allogeneic transplants, our study demonstrates that
multiple antiviral T cells recognizing the same HLA allomorph could pose an extra layer
of complexity for organ matching.
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INTRODUCTION
A hallmark of human antiviral T cells is their ability to recognize viral peptide antigen bound to
a self-human leukocyte antigen (HLA) on the surface of infected cells. Whilst this recognition
often displays exquisite specificity, it is not uncommon for some of these T cells to cross-react
with closely related peptide-HLA (pHLA) complexes, such as a peptide from a different viral strain
(1). Given that T cells are inherently cross-reactive, by nature of thymic selection (i.e., recognition
of self) and their interaction with foreign antigen in the periphery, cross-strain reactivity is a
beneficial property affording protection to mutant viral strains and preventing immune escape.
More remarkably, some T cells are also capable of recognizing apparently distinct pHLA including
non-self or allogeneic pHLA (2–4), self-pHLA that have undergone some form of perturbation
resulting in an altered self-peptide repertoire (5), and self-pHLA expressed in different tissues
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(6). These forms of heterologous immunity, otherwise known as
T cell cross-reactivity, are not beneficial to the host and can lead
to transplant rejection, drug hypersensitivity and autoimmunity,
respectively. Moreover, these potentially hazardous T cell
responses are the price paid to maintain immune potential
to combat the vast array of pathogenic challenges during a
lifetime. Hence, cross-reactivity is an intrinsic feature of T
cells, necessitated by the limited availability of unique human
T cell receptor (TCR) clonotypes (<108 distinct TCRs) to
maintain immunity against tremendous pathogenic diversity
(>1015 pHLA combinations) (7).
Childhood exposure to common viruses results in the
induction of a robust immune response that controls the
infection and generates long lasting immune memory. A small
proportion of some viruses (e.g., herpesviruses including Epstein-
Barr virus [EBV] and cytomegalovirus [CMV]) are able to evade
the immune response by entering into a latent state inside
the host cells. In fact, for these common herpesviruses up to
90% of individuals maintain viral latency by adulthood (8). The
persistence of a memory pool of T cells against the virus generally
controls outbreaks of viral reactivation. Recurrent reactivation
episodes maintain these memory T cells at high frequency,
facilitating rapid deployment and activation. Virally triggered
cross-reactive T cells have predominantly been explored in
infections where there is a high likelihood of their relevance
after transplantation. This is particularly so for EBV and CMV,
which establish latency in the host following naturally acquired
or vaccine-induced immunity. These viruses have been directly
implicated as risk factors associated with allograft rejection and
graft vs. host disease (8), with studies demonstrating that high
frequencies of herpesvirus-derived cross-reactive T cells (up to
85%) or clones (up to 45%) co-recognize alternate HLA allotypes
(3, 9–11). Whilst there is a high likelihood that cross-reactive T
cells are involved in clinical rejection (11–13), this has yet to be
formally proven.
Allo-HLA cross-reactivity by antiviral T cells has been
reported across a variety of HLA class I (A and B loci)
and II (DRB1 locus) restricted targets [reviewed in (14)].
In some instances, antiviral T cells derived from either the
same or heterologous viruses are capable of recognizing an
identical HLA allomorph. For instance, HLA-B∗44:02 is cross-
recognized by B∗08:01-restricted LC13 cytotoxic T lymphocytes
(CTL; EBV EBNA3A325−333), B
∗35:08-restricted SB27 CTL
(EBV BZLF152−64) and A
∗02:01-restricted 5101.1999.23 CTL
(herpes simplex virus-2 VP13/14289−298) (15–19). Given the
commonality of cross-reactive T cells and their potential to
contribute to adverse immune responses in allogeneic transplants
we wanted to determine whether multiple antiviral CTLs
recognizing the same HLA allomorphs would contribute an extra
layer of complexity for organ matching. This study examines the
extent of T cell cross-reactivity generated by three heterologous
viruses (i.e., EBV, CMV, and human immunodeficiency virus-1
Abbreviations: HD, healthy donor; HLA, human leukocyte antigen; LTR, lung
transplant recipient; PBMC, peripheral blood mononuclear cells; pHLA, peptide-
HLA; TCR, T cell receptor.
[HIV-1]) toward different HLA-B27 allotypes, which may have
clinical implications for transplantation.
MATERIALS AND METHODS
Study Participants and Peripheral Blood
Mononuclear Cells Isolation
Participant HLA typing is shown in Supplementary Table 1.
Peripheral blood mononuclear cells (PBMC) were isolated
by standard Ficoll-Paque (GE Healthcare, Uppsala, Sweden)
density gradient centrifugation and cryopreserved at −196◦C
until required.
Virus-Specific CD8+ T Cell Lines or Clones
EBV, CMV, or influenza A (IAV)-specific CD8+ T cell lines were
generated from chronically-infected individuals following in
vitro expansion of PBMC stimulated with gamma-irradiated
peptide-pulsed autologous cells (1µM peptide, 3,000 Rads)
at a 2:1 ratio in RF10 [composed of RPMI 1640 (Life
Technologies, Grand Island, NY) supplemented with 2mM
MEM non-essential amino acid solution (Life Technologies),
100mM HEPES (Life Techologies), 2mM L-glutamine (Life
Technologies), penicillin/streptomycin (Life Technologies),
50mM 2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO), 10%
heat-inactivated FCS (Sigma-Aldrich)] supplemented with 20
U/mL IL-2 (PeproTech, Rocky Hill, NJ) for 13 days at 37◦C,
5% CO2 as previously described (4, 11). Peptides for CMV:
HLA-A∗02:01-restricted pp65-derived NLVPMVATV (A2NLV)
epitope, EBV: HLA-B∗07:02-restricted EBNA-3A-derived
RPPIFIRRL (B7RPP) epitope and IAV: HLA-A
∗02:01-restricted
matrix protein-derived GILGFVFTL (A2GIL) epitope. Virus-
specific CD8+ T cell clones from chronically-infected individuals
were generated following single-cell sorting based on tetramer
staining using the HLA-B∗57:01-restricted TSTLQEQIGW
(B57TW10) epitope derived from HIV-1 Gag protein for A16 and
457 (20) or EBV: B7RPP epitope for HD9G6 (21), as previously
described (2, 22, 23).
Antigen-Presenting Cells and HLA Cell
Surface Expression
C1R transfected cells expressing different HLA-I molecules
(HLA-A∗02:01, -B∗07:02, -B∗57:01, -B∗27:01 to -B∗27:10) were
used as antigen-presenting cells (APCs), maintained in RF10
with selection antibiotics [Geneticin G418 (0.4–0.5 mg/ml;
Roche Diagnostics, Mannheim, Germany) or hygromycin B (0.3
mg/ml; Life Technologies, Carlsbad, CA)] as required (4, 24).
Increased HLA-I expression [compared to C1R Parental, which
has low levels of HLA-A and HLA-B expression and normal
HLA-C (25)] was confirmed via flow cytometry by indirect
staining with appropriate antibodies; anti-human pan HLA-I
(W6/32 hybridoma; for C1R.A∗02:01, C1R.B∗07:02, C1R.B∗57:01
shown in Supplementary Figure 1A), anti-human HLA-B7/27
(ME1 hybridoma; for C1R.B∗27:01 to C1R.B∗27:10 shown in
Supplementary Figure 1B) and a secondary goat anti-mouse
IgG phycoerythrin (PE) (1:200 dilution; Southern Biotech,
Birmingham, AL). All hybridomas were produced in-house.
Stained cells were acquired on LSRII flow cytometer [Becton
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Dickinson (BD), San Jose, CA]. Flow cytometry data was
analyzed using FlowJo software (TreeStar, Ashland, OR).
Specificity and Functionality of CD8+ T Cell
Lines or Clones
The specificity and activation of virus-specific CD8+ T cells were
assessed by anti-CD8 and tetramer (A2NLV or B7RPP) co-staining,
followed by intracellular staining (ICS) for functional Th1
cytokine production using flow cytometry (11, 26). Briefly, 2 ×
105 day 13 T cells were stimulated with media (negative control),
Dynabeads R© Human T-Activator anti-CD3/CD28 (positive
control; Life Technologies) or 1 × 105 APC (±1µM peptide)
for a total of 6 h at 37◦C, 5% CO2 with 10µg/mL brefeldin A
(Sigma-Aldrich) added for the last 4 h. T cells were phenotyped
with anti-CD8 PerCP Cy5.5 or allophycocyanin (APC) (1:20 or
1:40 dilution, clone SK1, BD Biosciences, San Jose, CA), HLA-
A2NLV or HLA-B7RPP tetramer (conjugated to either PE or APC)
and LIVE/DEAD fixable aqua stain (1:750 dilution, Thermo
Fisher Scientific, Waltham, MA). T cells were then fixed in 1%
paraformaldehyde (ProSciTech, Kirwan, Queensland, Australia),
permeabilized in 0.3% saponin (Sigma-Aldrich) containing anti-
IFNγ PE-Cy7 (1:250 dilution, clone B27, BD Biosciences) and
anti-TNFα V450 (1:400 dilution, clone Mab11, BD Biosciences),
then acquired on LSRII flow cytometer. Flow cytometry data was
analyzed using FlowJo software. The HIV-1 B57TW10 CD8
+ T
cell clones, A16 and 457, were assessed for functionality toward
cognate peptide by (i) staining of cell surface anti-CD3 V450 and
anti-CD137 APC (BD Biosciences) for 20min and then analyzed
on the FACSCanto II (BD) according to standard procedures, and
(ii) functional cytotoxicity against single HLA expressing K562
cell line loaded with cognate peptide, using target cell 7-AAD
uptake as readout, as previously published (27). This study shows
the data for A16, with 457 being published elsewhere (20). Gating
strategies are shown in Supplementary Figure 2. Tetramers were
produced in-house by refolding soluble HLA α-heavy chain-BirA
and β2-microglobulin with peptide to create monomers, which
were then conjugated at a 4:1 molar ratio to streptavidin-PE or
-APC (Life Technologies) (24).
αβTCR Identification
Virus-specific CD8+ T cells lines were incubated with 1µM
peptide or relevant peptide-pulsed C1R transfected cells for
2 h before detection of cytokine secretion using an anti-
IFNγ antibody (IFNγ Secretion Assay Detection Kit APC;
Miltenyi Biotec, Auburn, CA) as previously described (28).
CD8+ T cells were single-cell sorted directly into semi-skirted
96-well plates (Bio-Rad Laboratories Inc., USA) based on
tetramer specificity and ± IFNγ production (FACSAria I,
BD Biosciences operated by FlowCore, Monash University).
Sorted plates were immediately stored at −80◦C until required.
TCR analysis of paired complementarity determining region
(CDR)3α and β loops were carried out using multiplex
nested RT-PCR and sequencing of α and β gene products
as previously described (29). For virus-specific CD8+ T cell
clones, αβTCR usage was determined by DNA Sanger sequencing
using either TCR-specific PCR for HD9G6 (30) or next-
generation sequencing using published primer sequences (31) for
A16 and 457.
TCR Expression in SKW3.hCD8αβ Cells
Full-length human TCRα and TCRβ cDNA was cloned into
a self-cleaving 2A peptide-based pMIG vector as described
previously (32). HEK293T packaging cells were incubated with
4mg pEQ-pam3(-E) and 2mg pVSV-G packaging vectors, in
the presence of 4mg pMIG vector each containing a specific
TCR transgene using Lipofectamine 3000 (Life Technologies).
HEK293T cell culture supernatant containing virus particles
carrying the TCR transgene was then used to retrovirally
transduce GFP-tagged SKW3.hCD8αβ cells or GFP-tagged
SKW3.hCD8αβ.CD3 [for LTR5 TCR only (28)], which are
negative for endogenous TCRαβ but contain CD3 and signaling
components, as previously described (28). SKW3.hCD8αβ.TCR
(hereafter referred to as SKW3) cell lines were maintained in
RF10. Routine monitoring of TCR cell surface expression on
SKW3 transduced cells was performed using anti-CD3 PE-Cy7
(1:500 dilution, clone SK7, BD Biosciences), anti-CD8 PerCP
Cy5.5 (1:20 dilution, clone SK1, BD Biosciences) and GFP.
Gating strategy shown in Supplementary Figure 3. Activation of
SKW3.TCRs were assessed via cell surface staining with anti-
CD3 PE-Cy7 (1:500 dilution, clone SK7, BD Biosciences), anti-
CD8 PerCP Cy5.5 (1:20 dilution, clone SK1, BD Biosciences)
and anti-CD69 APC (1:50 dilution, clone L78; BD Biosciences)
following 16–20 h incubation with stimuli at 37◦C, 5% CO2.
A representative gating strategy for SKW3.HC5 is shown
in Supplementary Figure 4, with CD69 mean fluorescence
intensity (MFI) values calculated after gating on FSC vs. SSC,
single cells, GFP+ cells, live cells, CD3+CD8+ cells and then
CD69+ cells.
Statistical Analysis
Statistical significance was determined by non-parametric one-
way ANOVA (Kruskal-Wallis test) with post-hocDunn’s multiple
comparison test or unpaired Student’s t-test using Prism 8
(GraphPad) with ∗p < 0.05, ∗∗p < 0.01, and ∗∗∗∗p < 0.0001.
Error bars indicate the mean± SEM.
RESULTS
Generation of Virus-Specific CD8+ T Cell
Lines and Clones
Virus-specific CD8+ T cells can be generated following
stimulation with viral cognate peptide-pulsed autologous
PBMCs. To demonstrate both specificity and functionality,
in vitro expanded T cell lines or clones were co-stained with
anti-CD8 and tetramer phenotypic markers for identification of
virus-specific T cells. As expected, variations in the frequency
of expanded tetramer+CD8+ T cell lines were observed for
both EBV and CMV (Figures 1A,B, middle panels), ranging
between 32.6–90.7% (n = 6) and 6.15–74.0% (n = 2) of
the total CD8+ T cell population for B7RPP and A2NLV,
respectively. In addition, CD8+ T cell clones raised against
the HIV-1 B57TW10 epitope in patients A16 and 457 showed
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FIGURE 1 | Characterization of virus-specific CD8+ T cells. Virus-specific CD8+ T cell lines and clones for (A) EBV, (B) CMV, and (C) HIV-1 were examined for
specificity following either re-stimulation with HLA-restricted APCs pulsed with cognate viral peptide or bulk PBMC sorting, using both anti-CD8 and specific tetramer.
The functionality of virus-specific CD8+ tetramer+ T cells was assessed either using IFNγ production for T cell lines or via the CD137 activation marker for HIV-1 T cell
clones. Cells were gated on FSC vs. SSC, single cells, CD8+, CD8+tetramer+, CD8+ IFNγ+ cells. Representative plots are shown.
very high frequencies following tetramer-specific PBMC bulk
sorting (Figure 1C, middle panels), which were similar to the
high frequencies observed against the EBV-B7RPP epitope (i.e.,
HD9G6). To assess the functionality of the EBV- or CMV-specific
CD8+ T cell lines to produce the pro-inflammatory cytokine
IFNγ, cells were restimulated with HLA-restricted APCs
pulsed with cognate viral peptide. The frequency of IFNγ
production ranged from 17.2 to 67.0% and 38.4 to 68.2% of
the CD8+ tetramer+ T cell population for B7RPP and A2NLV,
respectively (Figures 1A,B, lower panels). For HD9G6, the
functionality of this B7RPP-specific CD8
+ T cell clone is
published elsewhere (21). For B57TW10-specific CD8
+ T cell
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clones A16 and 457, the activation marker CD137, which
induces downstream effects of proliferation and cytolytic
activity, was used to assess functionality when stimulated with
cognate TW10 peptide (Figure 1C), with data for 457 reported
elsewhere (20).
Increased Sensitivity for TCR
Cross-Reactivity Detection Using SKW3
Reporter Cells
We have previously reported that CMV-specific CD8+ T cells
raised against A2NLV were differentially cross-reactive toward
three HLA-B27 allotypes (B∗27:07 > B∗27:09 > B∗27:05). These
T cells were also shown to remain relatively stable following
lung transplantation, but increased significantly in response to
CMV reactivation (4, 11). Further characterization of the cross-
reactive A2NLV-specific TCR repertoires from two unrelated
individuals showed a striking similarity for the cross-reactive
TCR clonotype. Additionally, this study also demonstrated that
expression of cross-reactive TCRs in SKW3 cells was a robust
system that maintains specificity without the need for continuous
in vitro expansion of T cell lines or clones for further functional
immunoassays (28). In this study, we extended the HLA-B27
allotype panel (B∗27:01–B∗27:10) to map the immunogenic
FIGURE 2 | Activation of SKW3.A2NLV TCR cells by HLA-B27–expressing APCs. SKW3.TCR activation was measured using cell surface CD69 upregulation after
16–20 h stimulation with C1R.A*02:01 ± cognate NLV peptide and a panel of C1R.B27 transfectants. CD69 MFI values were calculated after gating on FSC vs. SSC,
single cells, GFP+ cells, live cells, CD3+CD8+ cells then CD69+ cells. Mean ± SEM are shown (a single experiment with triplicate data is shown from independent
biological replicates performed at least twice). Statistical significance denoted by *p < 0.05 and **p < 0. 01 was determined by repeated measures non-parametric
ANOVA (Kruskal–Wallis test) with post-hoc Dunn’s multiple comparison test.
TABLE 1 | Virus-specific αβTCR signatures.
Virus and
HLA/epitope
TCR α-chain β-chain References
TRAV CDR3 TRAJ TRBV CDR3 TRBJ
EBV
B7 RPP
LTR54.1 38-1 CAFSYNNNDMRF 43 4-1 CASSQETGIYTQYF 2-3
LTR54.2 38-1 CAFIQGAQKLVF 54 4-1 CASSQEAFNYEQYF 2-7
LTR117 38-1 CAFASSNTGKLIF 43 4-1 CASSQDIWTSGYTF 2-3
LTR119 38-2/DV8 CALGGGAQKLVF 54 28 CASRLGLGDREDEKLFF 1-4
HD9G6 14/DV4 CAMRDDTGGFKTIF 9 19 CASSISSGVAYEQYF 2-7 (21)
CMV
A2 NLV
HC5 3 CAVRGTNARLMF 31 12 CASSSVNEAFF 1-1 (28)
LTR5 3 CAVRNNNARLMF 31 12 CASSIVNEAFF 1-1 (28)
HIV-1
B57 TW10
A16.1 4 CLVGEVRGGFKTIF 9 4-3 CASSQARGGAETQYF 2-5
A16.2 4 CLVGGEDYKLSF 20 4-3 CASSQARGGAETQYF 2-5
457 39 CAVDINTSGTYKYIF 40 10-3 CAISRQGARQETQYF 2-5 (20)
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profiles of cross-reactive virus-specific T cells (SKW3.LTR5 and
SKW3.HC5), which were previously derived from two HLA-A2+
donors recognizing both the CMV A2NLV epitope and HLA-B27
molecules (28). Stimulation of both SKW3.LTR5 and SKW3.HC5
with our new panel of C1R.B27 allotypes reconfirmed our
previous findings of an immunogenic hierarchy (B∗27:07 >
B∗27:09 > B∗27:05) but also revealed additional cross-reactivity
toward B∗27:03 for SKW3.LTR5 and B∗27:10 > B∗27:03 >
B∗27:02 for SKW3.HC5. All negative, background (media and
C1R Parental, C1R.A∗02:01) and positive (CD3/CD28 beads,
C1R.A∗02:01+NLV) controls were as expected (Figure 2).
Given the utility of SKW3 reporter cells for profiling
TCR cross-reactivity, we adopted this approach to further
explore HLA-B27 allorecognition patterns by immunodominant
HLA-restricted virus-specific T cells. Here, several cognate
peptide-specific CD8+ T cells identified using either the ICS
immunoassay (i.e., T cell lines) or tetramer sorting (i.e.,
T cell clones) were sequenced for paired TCR α and β
chains. The highest frequency αβTCR was then selected for
retrovirus transduction into SKW3 cells (Table 1). Following
transduction, extremely high levels of clonality of >90% were
easily achieved and maintained by sorting the top 10% of
GFP+CD3+ cells if TCR expression decreased during long-term
sub-culturing (Figure 3).
Dissection of Virus-Specific TCR
Cross-Reactivity Toward HLA-B27
Allotypes Reveals Distinct Patterns of
Allorecognition
Here we investigated whether EBV-B7RPP-specific CD8
+ T
cells could cross-recognize HLA-B27 molecules as a potential
trigger of allorecognition. Following validation with the cognate
peptide, we re-stimulated our day 13 in vitro-expanded B7RPP-
specific CD8+ T cells, which were generated from five EBV-
seropositive individuals (HD14, LTR54, LTR117, LTR119, and
LTR130), against a panel of HLA-B27-expressing APCs in a
6 h ICS assay with functionality assessed via Th1 cytokine
production (i.e., TNFα+ or IFNγ+ alone or dual TNFα+IFNγ+).
Specificity of the B7RPP-specific CD8
+ T cells was confirmed
in all individuals by reactivity to C1R.B∗07:02 in the presence
of cognate RPP peptide. Remarkably, differential patterns of
HLA-B27 allorecognition were observed across these individuals.
Here, B7RPP-specific CD8
+ T cells from HD14 demonstrated a
moderate response to B∗27:02 and weak responses to B∗27:08,
LTR54 showed a very dominant response to B∗27:08 only,
LTR117 recognized several allotypes with B∗27:02 > B∗27:01
> B∗27:07 and similar levels for B∗27:03/08/09, LTR119 weakly
recognized B∗27:02/08 and LTR130 moderately responded to
B∗27:08. All negative, background (media and C1R Parental,
C1R.B∗07:02) and positive (CD3/CD28 beads) controls were as
expected (Figure 4A, Table 2). Therefore, for the first time, we
report a new model of EBV/HLA-B27 cross-reactivity that was
observed across multiple individuals.
To explore these HLA-B27 allorecognition patterns in
greater depth we generated SKW3.TCR cells expressing the
B7RPP-specific TCR observed at the highest frequency for
LTR54 (LTR54.1 and LTR54.2), LTR117 and LTR119, in
addition to the published HD9G6 TCR, which showed cross-
reactivity toward HLA-B∗40:01 (21) (Table 1). For LTR54,
two TCRs with the same α and β-chain variable regions but
different junction regions and CDR3 loops were observed. To
investigate whether these contrasting regions were pivotal for
allorecognition both TCRs were expressed in SKW3 cells. As
observed with the immunogenic hierarchies of CMV A2NLV
cross-reactive TCRs for HC5 and LTR5, we demonstrated greater
sensitivity of allorecognition using SKW3.TCR reporter cells.
The patterns were as follows: LTR54.1 strongly recognized
B∗27:08 and to a weaker extent B∗27:02/07/04/06/09, whilst in
comparison LTR54.2 also strongly responded to B∗27:08 but
weakly recognized alternate B27 allotypes B∗27:06/01/02/04/07;
LTR117 recognized most of the allotypes with the strongest
FIGURE 3 | αβTCR expression of SKW3 reporter cells. Retrovirally transduced SKW3 cells expressing cross-reactive virus-specific αβTCRs for (A) EBV, (B) CMV, and
(C) HIV-1 were monitored for stable cell surface TCR expression. Cells were gated on FSC vs. SSC, single cells, GFP+CD3+ cells. Representative plots are shown.
Frontiers in Immunology | www.frontiersin.org 6 February 2020 | Volume 11 | Article 248
Rowntree et al. Antiviral TCR Cross-Reactivity Toward HLA-B27
FIGURE 4 | EBV B7RPP allorecognition of HLA-B27 molecules. (A) Day 13 in vitro expanded B7RPP-specific CD8
+ T cells were stimulated with C1R.B*07:02 ±
cognate RPP peptide and a panel of C1R.B27 transfectants before performing a 6 h ICS, with T cell responses measured by the production of Th1 cytokines (i.e.,
TNFα+ or IFNγ+ alone or dual TNFα+ IFNγ+) after gating on CD8+tetramer+ T cells. (B) SKW3.TCR activation was measured using cell surface CD69 upregulation
after 16–20 h stimulation with C1R.B*07:02 ± cognate RPP peptide and a panel of C1R.B27 transfectants. CD69 MFI values were calculated after gating on FSC vs.
SSC, single cells, GFP+ cells, live cells, CD3+CD8+ cells then CD69+ cells. Mean ± SEM are shown (single experiments with duplicate data for ICS assay and CD69
assay are shown from independent biological replicates each performed at least twice).
toward B∗27:01/02 followed by B∗27:10/08/04/09/06/07;
LTR119 showed weak responses across several allotypes
with B∗27:02/07 followed by B∗27:08/04; and finally HD9G6
strongly recognized B∗27:08/01 then B∗27:05/07/09/02/04/03
(Figure 4B, Table 2).
A recent report highlighted that HIV-1-specific memory
T cells generated from Gag B57TW10 epitope can mediate
abacavir-induced hypersensitivity reactions through molecular
mimicry (20). Therefore, we explored the alloreactive potential
of B57TW10-specific CD8
+ T cells toward HLA-B27. TCRs
from two T cell clones (A16 and 457) raised against the
Gag B57TW10 epitope were expressed in SKW3 cells for
functional evaluation. Sequencing of the A16T cell clone
revealed two α-chains with different junction regions and
CDR3 loops, therefore both TCRs were independently
expressed in SKW3 cells (Table 1). Strikingly, comparisons
of SKW3.A16.1 and SKW3.A16.2 show a 9-fold difference in
recognition of C1R.B∗57:01 cells presenting cognate TW10
peptide (positive control), suggesting that A16.2 TCR is the
primary driver of the cognate peptide recognition. Yet despite
this, SKW3.A16.1 recognizes both B∗27:07 and B∗27:05 at a
similar magnitude to B∗27:05 allorecognition by SKW3.A16.2.
For SKW3.457, responses were biased toward B∗27:01 and
B∗27:02 (Figure 5, Table 2). Furthermore, we examined whether
immunodominant IAV A2GIL-specific CD8
+ T cells, from
an alternate RNA virus that induces acute viral infection,
could also alloreact toward HLA-B27 allotypes. Here, a total
of six healthy donors were screened, and interestingly no
significant allorecognition was observed above background
levels (Supplementary Figure 5).
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TABLE 2 | Comparison of T cell cross-reactivity using cellular immunoassays.
Assays: ICS for T cells, CD69 upregulation for TCR.
Cognate Viral Peptide Presented by
HLA-B27 Allotypes Does Not Confer
Additional Immunogenicity
To demonstrate that virus-specific TCR cross-reactivity toward
HLA-B27 allotypes is bona fide and cannot be influenced by
the presence of cognate peptide we examined the immune
response of SKW.HC5 (i.e., CMV A2NLV), SKW3.LTR54.1 (i.e.,
EBV B7RPP), and SKW3.457 (i.e., HIV-1 B57TW10) toward a
panel of HLA-B27 stimulators in the absence and presence of
cognate peptide. All SKW3.TCR lines generated responses to
negative, background (media and C1R Parental, C1R.A∗02:01
or C1R.B∗07:02 or C1R.B∗57:01) and positive (CD3/CD28
beads and C1R.A∗02:01+NLV or C1R.B∗07:02+RPP or
C1R.B∗57:01+TW10) controls as expected. Importantly, no
differences in the magnitude of HLA-B27 allorecognition was
observed between APCs in the presence or absence of cognate
peptide across all three SKW3.TCR lines. However, surprisingly
a statistically significant difference was determined following
stimulation of SKW.HC5 with C1R.B∗27:05+NLV (p < 0.0001),
which could indicate a role for the presented peptide, however
this requires further confirmation (Figure 6).
DISCUSSION
In this study, we examined the cross-reactive potential of CD8+
T cells specific for immunodominant epitopes derived from
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FIGURE 5 | HIV-1 B57TW10 allorecognition of HLA-B27 molecules. TCR activation was measured using cell surface CD69 upregulation after 16–20 h stimulation with
C1R.B*57:01 ± cognate TW10 peptide and a panel of C1R.B27 transfectants. CD69 MFI values were calculated after gating on FSC vs. SSC, single cells, GFP+
cells, live cells, CD3+CD8+ cells then CD69+ cells. Mean ± SEM are shown (a single experiment with duplicate data is shown from independent biological replicates
performed at least twice).
three different chronic viruses (i.e., CMV, EBV, and HIV-1),
presented by commonly expressed HLA (i.e., A2, B7, and B57).
We demonstrated that these virus-specific CD8+ TCRs were
capable of vigorous cross-reactivity toward specific HLA-B27
allotypes, and that the immune responses were hierarchical and
varied considerably across the three chronic viruses.
Whilst, we previously reported a defined pattern of strong
HLA-B27T cell cross-reactivity (B∗27:07 > 09 > 05) by CMV
A2NLV CD8
+ TCRs for both LTR5 and HC5 (11, 28), this
study extended the number of B27 subtypes examined and
revealed additional cross-reactivity toward B∗27:10 > 03 >
02 for HC5. Interestingly, despite subtle sequence differences
in the CDR3 regions of both the α- and β-chains (2 and 1
amino acids, respectively) between LTR5 and HC5, the fine
specificity of strong TCR interactions with B∗27:07/09 allotypes
were maintained. The data suggests that the composition of the
allopeptide(s) presented by each HLA-B27 allomorph are similar
or alternatively, of high affinity and that molecular flexibility
of the CDR3 loops aids promotion of TCR engagement (33,
34). In contrast, weaker responses toward B∗27:02/03/10 show
delineation in TCR interaction, with LTR5 not demonstrating
recognition of these allotypes, which may be due to weak
TCR interactions below the assay sensitivity threshold. This
suggests that the allopeptide contribution required to form the
ternary complex is impacted by the variability observed in the
CDR3 regions, which is supported by structural studies of the
murine 2C TCR demonstrating that variations in the CDR3α
loop dictated TCR affinity and cross-reactivity between distinct
ligands (35). Indeed, the importance of the TCR variable domains
in promoting high affinity interactions with pHLA complexes
was also shown with the human HLA-A2-restricted cancer
antigen MART-1 (36). Further investigations are required to
decipher the allopeptide(s) presented by these HLA-B27 allotypes
and determine their exact role in conferring cross-reactivity.
We next examined the magnitude of cross-reactivity exhibited
by EBV-specific B7RPP CD8
+ T cells toward HLA-B27 allotypes.
In the five HLA-B7+ individuals, including a healthy donor
and immunosuppressed patients, allorecognition resulted in
production of proinflammatory Th1 cytokines (IFNγ and TNFα)
mainly toward either B∗27:02 or B∗27:08. Although, it should be
noted that an additional screen of four healthy donors showed
no HLA-B27 cross-reactivity, suggesting that allorecognition is
driven by private TCR usage. The B7RPP CD8
+ TCR repertoires
were sequenced for three of these individuals to determine
their clonotypic profiles. Interestingly, only two clonotypes were
observed for LTR54 (i.e., LTR54.1 and LTR54.2), which differed
in the CDR3 and J regions of both TCRα- and β-chains. Both
TCRs were expressed in SKW3 cells for further functional
validation. Additionally, comparison of the B7RPP CD8
+ TCR
clonotypes showed a high degree of similarity between LTR54.1
and LTR117, with differences only noted in the CDR3α- and
β-loops. Whilst, LTR119 and the previously reported B7RPP
CD8+ T cell clone, HD9G6 (21), are vastly different from the
other TCRs in this cohort. Interestingly, the strongest TCR
cross-reactivity was relatively restricted to B∗27:08 (LTR54.1,
LTR54.2, HD9G6) and B∗27:02 (LTR117), although there was a
degree of allorecognition toward other subtypes for most TCRs.
These observations highlight that both private (i.e., LTR119 and
HD9G6) and shared (i.e., LTR54.1 and LTR117) TCR specificities
contribute to cross-reactivity, and that the cross-reactive pattern
diversity is dependent on the Vβ region (2, 15, 16). Furthermore,
Amir et al. (2) also reported that T cell clones with identical Vβ
regions from the same individual held private specificities and
generated different alloreactions. For example, in donor BDV
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FIGURE 6 | HLA-B27 presentation of cognate viral peptide does not confer additional immunogenicity. (A) SKW.HC5 (i.e., CMV A2NLV ), (B) SKW3.LTR54.1 (i.e., EBV
B7RPP), and (C) SKW3.457 (i.e., HIV-1 B57TW10) TCR activation was measured using cell surface CD69 upregulation after 16–20 h stimulation with HLA-restricted
C1R transfectants ± cognate peptide and a panel of C1R.B27 transfectants. CD69 MFI values were calculated after gating on FSC vs. SSC, single cells, GFP+ cells,
live cells, CD3+CD8+ cells then CD69+ cells. Mean ± SEM are shown (single experiment with triplicate data). Statistical significance using unpaired Student’s t-test is
denoted by ****p < 0.0001.
a T cell clone raised against CMV B7RPHERNGFTVL with TCR
Vβ7.2 recognized DRB1∗08:01, whilst another T cell clone from
same individual with the identical Vβ did not. Additionally,
in donor FKR an influenza A2GIL T cell clone with Vβ17
recognized allogeneic HLA-B∗64:01 but another T cell clone with
the identical Vβ failed. These T cell clones had private differences
in TCR sequence, which effectively abrogated alloreactivity.
For the herpesvirus TCRs, the allorecognition hierarchy
remained relatively static for the strongest responses, but this
was not observed in the case of HIV-1 B57TW10 CD8
+ TCRs in
that 457 and A16 TCRs were completely focused toward different
HLA-B27 allotypes. Here, we show that 457 TCR cross-reacted
strongly toward B∗27:02 > 01, with two TCRs derived from A16
strongly recognizing B∗27:05/07 for A16.1 and B∗27:05 for A16.2.
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Comparison of their TCRs revealed that their signatures were
completely different, supporting that the B57TW10 specificity is
driven by private TCR usage in these two individuals. Particularly
of interest was the dual expression of two different TCRα-
chains from the A16T cell clone, which when independently
expressed in SKW3 reporter cells, showed reactivity differences
not only toward the B27 subtypes but also importantly against
the cognate antigen. We observed that the A16.2 TCR was
geared toward cognate antigen recognition, with the A16.1 TCR
being more alloreactive. Up to 30% of human peripheral T
cells naturally express dual TCRα-chains (37), with multiple
studies demonstrating that the allelic inclusion facilitates a
heightened immune response by providing an additional chance
for antigen recognition and engagement [extensively reviewed
in (38)].
So, what drives the preferential HLA-B27 allorecognition
displayed by these virus-specific TCRs? Undoubtedly, the
polymorphic nature of the B27 molecule itself greatly influences
the peptide cargo being displayed to surveying T cells (Figure 7).
In our study, the A2NLV CD8
+ TCRs preferentially bind to
B∗27:07/09/05, which differ by 1 (B∗27:09) and 5 (B∗27:07)
amino acids compared to the consensus B∗27:05 allotype. These
polymorphisms directly impact the D/E (position 114, peptide
contacts P5–P7) and F (position 116, peptide contact P9) peptide-
binding pockets, which are known immunological hot spots
for non-permissive HLA mismatches in transplantation (39–43).
Given that the public A2NLV CD8
+ TCR co-recognizes these
three molecules and their relative impact on the peptide-binding
pockets D/E and F, suggests that each may be presenting an
alternate allopeptide with affinity above a threshold to promote
TCR engagement. This is supported by the prototypic HLA-B8-
restricted LC13 TCR which is capable of engaging with HLA-
B∗44:05 presenting either an allotype or mimotope (18). In
addition, we cannot exclude that the same allopeptidemay also be
presented by all HLA-B27 molecules, with allorecognition being
impacted by differences in conformational flexibility. Indeed,
a study by Loll et al. demonstrated that a HLA-B27-derived
self-peptide derived from vasoactive intestinal peptide receptor
type 1 (epitope; RRKWRRWHL) is differentially presented by
AS-associated B∗27:04 and B∗27:05 compared to the non-AS-
associated B∗27:06 and B∗27:09 due to structural variations in
molecular dynamics (44). For B7RPP CD8
+ TCRs, recognition
was focused toward B∗27:08/02/01, with B∗27:01 and B∗27:02
differing by a single amino acid (position 80) and both differing
from B∗27:08 by 5 amino acids (positions 77, 80–83), all of
which also influence the F peptide-binding pocket (Figure 7).
Finally, for the B57TW10 CD8
+ TCRs we observed completely
divergent recognition of B27 allotypes by 457 (B∗27:01/02) and
A16 (B∗27:05/07). However, a common feature is involvement of
the F pocket at positions 80 and 116, respectively. Interestingly,
the F pocket not only determines the carboxy terminal motif of
HLA-I peptides (45), but in other HLA-B27 allotypes has also
been shown to affect anchoring sites (i.e., B∗27:06; P3, P-2,
and P) (46). Moreover, positions 114 and 116 are important
for the chaperone tapasin, involved in loading of optimal
peptides on HLA-I molecules (47, 48). Whilst, the identification
of allopeptides has been a major limiting factor hampering
FIGURE 7 | HLA-B27 polymorphisms and amino acid chemical properties.
B27:01-B*27:04, B*27:06-B*27:10 amino acid polymorphisms were
compared to the consensus sequence for B*27:05. The chemical properties of
substituted residues and their influence on HLA-I peptide-binding pockets
are detailed.
translational impact in clinical studies, further investigations are
warranted to assess the true impact of T cell cross-reactivity.
Here we analyzed three HLA-B27 cross-reactivity models,
including our newly identified EBV/HLA-B27 model, using
T cell lines/clones and the more fine-tuned TCR-specific
SKW3 cell lines, to reveal the diversity and breadth of cross-
reactivity against different HLA-B27 allotypes. Specifically, we
showed that cross-reactive TCRs (LTR5, HC5, LTR119, A16.1)
derived from the three heterologous viruses were capable of
recognizing B∗27:07, with cross-reactive TCRs from two viruses
recognizing either B∗27:01 (LTR117, HD9G6, 457), B∗27:02
(LTR119, 457), or B∗27:05 (HC5, A16.1, A16.2). Collectively,
this study demonstrated selective TCR cross-reactivity toward
HLA-B27 allotypes by chronic latent viruses, which may evoke
clinically relevant alloreactivity following transplantation.
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Supplementary Figure 1 | HLA cell surface expression of APCs. APCs were
stained with primary antibody either (A) pan-HLA-I W6/32 or (B) anti-HLA-B7/27
ME1, followed by secondary goat anti-mouse IgG PE. A secondary (2◦) antibody
alone control was used for background staining. MFI was calculated after gating
FSC vs. SSC then primary antibody histogram. Representative plots are shown.
Supplementary Figure 2 | Gating strategy for specificity and functionality of
virus-specific CD8+ T cells. Representative virus-specific CD8+ tetramer+ T cells
was assessed for either (A) IFNγ production with cells gated on FSC vs. SSC,
single cells, live cells, CD8+, CD8+tetramer+, and CD8+ IFNγ+ cells or (B) CD137
activation with cells gated on FSC vs. SSC, CD3+ or CD8+, CD8+tetramer+, and
CD3+CD137+ cells.
Supplementary Figure 3 | Gating strategy for SKW3.TCR expression.
Representative cell surface TCR expression for SKW3.LTR119 is shown. Cells
were gated on FSC vs. SSC, single cells, GFP+CD3+ cells.
Supplementary Figure 4 | Gating strategy for CD69 upregulation assay.
Representative CD69 cell surface upregulation for SKW3.HC5 is shown following
stimulation with media, C1R.A∗02:01+NLV (cognate peptide), C1R.B∗27:01
(non-cross-reactive B27 allele) and C1R. B∗27:07 (cross-reactive B27 allele).
CD69 MFI values were calculated after gating on FSC vs. SSC, single cells, GFP+
cells, live cells, CD3+CD8+ cells, and then CD69+ cells.
Supplementary Figure 5 | IAV A2GIL allorecognition of HLA-B27 molecules. (A)
Representative gating strategy of NM003 d13 A2GIL-specific CD8
+ T cells
stimulated with C1R.A∗02:01+GIL peptide; FSC vs. SSC, single cells, live cells,
CD8+, CD8+tetramer+ and IFNγ+TNFα+ cells. (B) Day 13 in vitro expanded
A2GIL-specific CD8
+ T cells were stimulated with C1R.A∗02:01 ± cognate GIL
peptide and a panel of C1R.B27 transfectants before performing a 6 h ICS, with T
cell responses measured by the production of Th1 cytokines (i.e., TNFα+ or IFNγ+
alone or dual TNFα+ IFNγ+) after gating on CD8+tetramer+ T cells. Mean ± SEM
are shown (single experiment with duplicate data).
Supplementary Table 1 | HLA class I typing of study participants.
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